TNF and inflammatory bowel disease: Although clinically effective, biologic treatments are costly, and access in some countries can be limited owing to budgetary constraints.7 In recent years, several biosimilar drugs have been developed and approved for use in Europe for the treatment of IBD.8 As a result, a range of less costly treatment options is now available for the management of IBD, which will likely enable more widespread use of anti-TNF biologics.